PSMA x 4-1BB x albumin

更新于：2024-11-01

基本信息

关联

项与 PSMA x 4-1BB x albumin 相关的药物

CB-307

靶点

4-1BB x PSMA x albumin

作用机制

4-1BB激动剂 [+2]

在研机构

Crescendo Biologics Ltd.

原研机构

Crescendo Bioscience LLC

在研适应症

PSMA阳性去势抵抗性前列腺癌 [+2]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与 PSMA x 4-1BB x albumin 相关的临床试验

NL-OMON51775 / CompletedN/A

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions - CB307 Radio-labeled sub-study

开始日期2023-07-17

申办/合作机构-

NCT05836623 / Active, not recruiting临床1期

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA- Tumour Lesions (A Sub-study of CBT307-1 Study - EUDRACT 2019-004584-46)

CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic solid tumours that are PSMA+.

开始日期2022-12-20

申办/合作机构

Crescendo Biologics Ltd.

[+1]

NL-OMON52294 / RecruitingN/A

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA) - POTENTIA

开始日期2021-10-01

申办/合作机构

Crescendo Biologics Ltd.

100 项与 PSMA x 4-1BB x albumin 相关的临床结果

登录后查看更多信息

100 项与 PSMA x 4-1BB x albumin 相关的转化医学

登录后查看更多信息

0 项与 PSMA x 4-1BB x albumin 相关的专利（医药）

登录后查看更多信息

项与 PSMA x 4-1BB x albumin 相关的文献（医药）

2024-02-01·Neoplasia

Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents

Article

作者: Galson-Holt, Laurie ; Kwon, Hyeyoung ; Vance, Steven ; Kopp, Anna ; Thurber, Greg M ; Legg, James ; Johnston, Colette

Bispecific agents are a rapidly growing class of cancer therapeutics, and immune targeted bispecific agents have the potential to expand functionality well beyond monoclonal antibody agents. Humabodies⁎ are fully human single domain antibodies that can be linked in a modular fashion to form multispecific therapeutics. However, the effect of heterogeneous delivery on the efficacy of crosslinking bispecific agents is currently unclear. In this work, we utilize a PSMA-CD137 Humabody with an albumin binding half-life extension (HLE) domain to determine the impact of tissue penetration on T cell activating bispecific agents. Using heterotypic spheroids, we demonstrate that increased tissue penetration results in higher T cell activation at sub-saturating concentrations. Next, we tested the effect of two different albumin binding moieties on tissue distribution using albumin-specific HLE domains with varying affinities for albumin and a non-specific lipophilic dye. The results show that a specific binding mechanism to albumin does not influence tissue penetration, but a non-specific mechanism reduced both spheroid uptake and distribution in the presence of albumin. These results highlight the potential importance of tissue penetration on bispecific agent efficacy and describe how the design parameters including albumin-binding domains can be selected to maximize the efficacy of bispecific agents.